Transgenomic (PRPO)
(Delayed Data from NSDQ)
$6.03 USD
-0.15 (-2.43%)
Updated Apr 26, 2024 03:41 PM ET
After-Market: $6.03 +0.01 (0.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Transgenomic, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 15 | 9 | 9 | 6 | 3 |
Cost Of Goods | 9 | 7 | 6 | 5 | 3 |
Gross Profit | 6 | 3 | 2 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 14 | 15 | 12 | 10 | 11 |
Income After Depreciation & Amortization | -8 | -13 | -10 | -9 | -11 |
Non-Operating Income | 2 | 1 | 1 | -1 | -4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -6 | -12 | -9 | -11 | -13 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -6 | -12 | -9 | -11 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -6 | -12 | -9 | -11 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -11 | -8 | -7 | -8 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 1 | 2 | 3 |
Income After Depreciation & Amortization | -8 | -13 | -10 | -9 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.30 | 1.14 | 1.06 | 0.82 | 0.29 |
Diluted EPS Before Non-Recurring Items | -5.56 | -10.80 | -8.00 | -15.60 | -46.60 |
Diluted Net EPS (GAAP) | -4.51 | -10.80 | -8.00 | -17.00 | -46.60 |
Fiscal Year end for Transgenomic, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 4.33 | 4.52 | 3.53 | 2.82 |
Cost Of Goods | NA | 2.32 | 2.63 | 2.16 | 2.07 |
Gross Profit | NA | 2.01 | 1.89 | 1.37 | 0.75 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.87 | 3.33 | 3.66 | 3.78 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.86 | -1.44 | -2.29 | -3.03 |
Non-Operating Income | NA | 1.79 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 0.01 | 0.01 | 0.00 | 0.00 |
Pretax Income | NA | 0.92 | -1.46 | -2.29 | -3.03 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 0.92 | -1.46 | -2.29 | -3.03 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 0.92 | -1.46 | -2.29 | -3.03 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 1.06 | 1.40 | 1.22 | 1.16 |
Diluted EPS Before Non-Recurring Items | NA | -0.41 | -1.04 | -1.80 | -2.60 |
Diluted Net EPS (GAAP) | NA | 0.93 | -1.04 | -1.80 | -2.60 |